Veradermics Incorporated (MANE)
NYSE: MANEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
MANE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.64B
- EPS (TTM)
- -$4.24
- Dividend yield
- None
- 52-week range
- 32.00 – 131.24
- Day range
- 108.84 – 113.43
- Volume / Avg
- 655.07K / 725.40K
- Beta
- —
- Shares outstanding
- 41.78M
52-week range
MANE stock today
Veradermics (MANE) closed at $110.95 on Oct 7, up 1.83% (+$1.99), versus the S&P 500's 0.22% decline. Shares are 15.5% below their 52-week high of $131.24, set on Jul 1, 2026 and 246.7% above the 52-week low of $32.00, in the middle of the past year's range. Veradermics has posted a net loss over the last twelve months (EPS of -$4.24), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Veradermics
Company profileVeradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Reid Waldman M.D.
- Headquarters
- New Haven, CT
- Employees
- 37
- IPO year
- 2026
- Website
- veradermics.com
Financial highlights
Full financialsVeradermics reported a net loss of $70.0 million, compared with a loss of $26.5 million a year earlier. Diluted earnings per share came in at -$111.91.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | — | — |
| Growth | — | — |
| Net income | $-70.00M | $-26.49M |
| EPS (diluted) | $-111.91 | $-37.05 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$163.50+47.36%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q2 2026)
- Aug 11, 2026
- EPS actual vs est.
- $-0.58 vs —
Veradermics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DNTHDianthus Therapeutics Inc. | 84.88 | -0.61% | $4.75B | vs MANE |
| EWTXEdgewise Therapeutics Inc. | 39.57 | -1.12% | $4.30B | vs MANE |
| INDVIndivior Pharmaceuticals Inc. | 36.13 | +0.64% | $4.26B | vs MANE |
| ERASErasca Inc. | 14.12 | -1.26% | $4.94B | vs MANE |
| ABCLAbCellera Biologics Inc. | 12.83 | -2.43% | $4.16B | vs MANE |
| TVTXTravere Therapeutics Inc. | 53.44 | -4.54% | $5.04B | vs MANE |
| GRFSGrifols S.A. ADR | 7.50 | -0.27% | $5.10B | vs MANE |
| COGTCogent Biosciences Inc. | 30.14 | -0.79% | $5.23B | vs MANE |
Indexes, lists and sector
Veradermics stock FAQ
What is Veradermics's stock price today?
MANE last traded at $110.95 as of Oct 7, 4:00 PM EDT, up 1.83% on the day. Prices are delayed at least 15 minutes.
Who is Veradermics's CEO?
Dr. Reid Waldman M.D. is the chief executive officer of Veradermics Incorporated, which has about 37 employees.
What is the MANE 52-week high?
The 52-week high for MANE is $131.24 and the 52-week low is $32.00. The stock is currently 15.5% below its high.